MarketCap
AbCellera Biologics ABCL
$ 10.89
4.11%
Facebook
X
Telegram
AbCellera Biologics Total Liabilities | ABCL
Annual Total Liabilities AbCellera Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 390 M | 304 M | 336 M | 308 M | 293 M | 175 M | 13.2 M | 9.88 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 390 M | 9.88 M | 229 M |
Quarterly Total Liabilities AbCellera Biologics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 412 M | 369 M | 392 M | 395 M | 321 M | 304 M | 315 M | 302 M | 333 M | 336 M | 329 M | 342 M | 289 M | 308 M | 302 M | 381 M | 385 M | 293 M | 219 M | 184 M | 171 M | 175 M | 175 M | 175 M | 175 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 412 M | 171 M | 295 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
1.04 B | - | - | - |  Russia |
 |
AbbVie
ABBV
|
97.3 B | $ 257.12 | 0.86 % | $ 455 B |  USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
459 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
69.4 M | - | -14.46 % | $ 27.9 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
37.9 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
234 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Advaxis
ADXS
|
2.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
60.4 M | $ 5.42 | 0.18 % | $ 287 M | USA |
 |
iTeos Therapeutics
ITOS
|
96.7 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
8.23 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
140 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
17.8 M | - | - | $ 28.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
55.9 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
77.4 M | $ 2.0 | 0.3 % | $ 726 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
51.9 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
18 M | $ 5.12 | 0.1 % | $ 981 M |  Canada |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
NextCure
NXTC
|
15.2 M | $ 7.0 | 0.55 % | $ 19.9 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |
 |
Nanobiotix S.A.
NBTX
|
152 M | $ 37.01 | 0.27 % | $ 1.77 T |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
337 M | $ 27.83 | 0.32 % | $ 4.69 B | USA |
 |
Axcella Health
AXLA
|
14.8 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
42.8 M | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
Achieve Life Sciences
ACHV
|
20.3 M | $ 7.06 | 0.41 % | $ 308 M | USA |
 |
Baudax Bio
BXRX
|
34.3 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
8.28 M | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
118 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
140 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
276 M | - | - | $ 789 M | USA |
 |
AC Immune SA
ACIU
|
109 M | $ 2.76 | 2.6 % | $ 278 M |  Schweiz |
|
Cerevel Therapeutics Holdings
CERE
|
570 M | - | - | $ 7.29 B | USA |
 |
Aclaris Therapeutics
ACRS
|
57.4 M | $ 5.32 | 1.27 % | $ 652 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Adagene
ADAG
|
26.4 M | $ 3.4 | 2.72 % | $ 201 M |  China |
 |
ADC Therapeutics SA
ADCT
|
509 M | $ 1.07 | 0.45 % | $ 136 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
1.4 M | $ 4.9 | 0.08 % | $ 3.28 M | USA |
 |
ADMA Biologics
ADMA
|
147 M | $ 9.23 | 0.16 % | $ 2.2 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
288 M | $ 24.2 | 0.08 % | $ 3.67 B | USA |
 |
Agenus
AGEN
|
387 M | $ 6.94 | 0.73 % | $ 206 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
104 M | $ 33.6 | 0.16 % | $ 1.95 B | USA |